Heron Therapeutics Inc HRTX:NASDAQ

Last Price$19.29NASDAQ Previous Close - Last Trade as of 4:15PM ET 6/05/20

Today's Change+0.86(4.67%)
Bid (Size)$19.16 (23)
Ask (Size)$19.75 (1)
Day Low / High$18.56 - 19.51
Volume882.3 K
 

View Biotechnology IndustryPeer Comparison as of 06/05/2020

 

Heron Therapeutics Inc ( NASDAQ )

Price: $19.29
Change: +0.86 (4.67%)
Volume: 882.3 K
4:15PM ET 6/05/2020
 
 

Epizyme Inc ( NASDAQ )

Price: $17.18
Change: +0.07 (0.41%)
Volume: 770.4 K
4:15PM ET 6/05/2020
 
 

Xencor Inc ( NASDAQ )

Price: $30.01
Change: +0.14 (0.49%)
Volume: 412.0 K
4:15PM ET 6/05/2020
 
 

Akebia Therapeutics Inc ( NASDAQ )

Price: $11.96
Change: -0.22 (1.85%)
Volume: 1.2 M
4:15PM ET 6/05/2020
 
 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $22.67
Change: +2.39 (11.82%)
Volume: 1.2 M
3:59PM ET 6/05/2020
 

Read more news Recent News

Analyst Actions: Guggenheim Starts Heron Therapeutics at Buy With $24 Price Target
9:28AM ET 5/27/2020 MT Newswires

Heron Therapeutics (HRTX) has an average analyst rating of buy, with an average price target of $42. Price: 19.05, Change: +0.61, Percent Change: +3.31 ...

Heron Therapeutics Commences Clinical Trial of Post-Operative Pain Medication
9:32AM ET 5/18/2020 MT Newswires

Heron Therapeutics (HRTX) said Monday that it has begun a phase 1b/2 clinical trial of HTX-034, the company's next-generation product for the treatment of...

Heron Therapeutics Q1 Loss Narrows, Revenue Declines
12:18PM ET 5/06/2020 MT Newswires

Heron Therapeutics (HRTX) on Wednesday posted a Q1 loss of $0.57, narrowing from $0.80 loss a year ago. Analysts polled by Capital IQ had expected a loss...

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Company Profile

Business DescriptionHeron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA. View company web site for more details
Address4242 Campus Point Court
San Diego, California 92121
Phone+1.858.251.4400
Number of Employees198
Recent SEC Filing06/04/20208-K
President, Chief Executive Officer & DirectorBarry D. Quart
Chief Financial Officer & Senior VP-FinanceRobert E. Hoffman
Chief Scientific Officer & SVP-PharmaceuticalThomas B. Ottoboni
Chief Medical OfficerChris M. Storgard

Company Highlights

Price Open$19.00
Previous Close$18.43
52 Week Range$9.60 - 26.81
Market Capitalization$1.7 B
Shares Outstanding90.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.27
Beta vs. S&P 500N/A
Revenue$77.5 M
Net Profit Margin-138.31%
Return on Equity-56.85%

Analyst Ratings as of 05/22/2020

Buy
10
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset